Hirabezol D 30mg/20mg Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related acid-peptic disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The synergistic action of these agents provides both symptomatic relief and addresses the underlying pathophysiology of acid reflux and delayed gastric emptying. Hirabezol D is typically administered orally once daily, preferably before meals, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms due to Domperidone. Caution is advised in patients with cardiac arrhythmias, hepatic impairment, or those on concomitant medications that prolong the QT interval. Hirabezol D should be used under medical supervision, with monitoring for efficacy and potential side effects to ensure optimal therapeutic outcomes.